TY - JOUR
T1 - HIV induces TRAIL sensitivity in hepatocytes
AU - Babu, Challagundla K.
AU - Suwansrinon, Kanitta
AU - Bren, Gary D.
AU - Badley, Andrew D.
AU - Rizza, Stacey A.
N1 - Funding Information:
Funding: Dr. Andrew Badley is supported by grants from the National Institutes of Health (R01 AI62261 and R01 AI40384), and the Burroughs Wellcome Fund’s Clinical Scientist Award in Translational Research (ID#1005160). Dr. Stacey Rizza is supported by a grant from the National Institute of Health (R21DK 77575-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2009 Babu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2009
Y1 - 2009
N2 - Background: HIV infected patients have an increased susceptibility to liver disease due to Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), alcoholic, and non-alcoholic steatohepatitis. Clinically, this results in limited options for antiretroviral therapy and accelerated rates of liver disease, causing liver disease to be the second leading cause of death for HIV infected patients. The mechanisms causing this propensity for liver dysfunction during HIV remains unknown. Methodology/Principal Findings: We demonstrate that HIV and/or the HIV glycoprotein gp120 ligation of CXCR4 on hepatocytes selectively up-regulates TRAIL R2 expression and confers an acquired sensitivity to TRAIL mediated apoptosis which is mediated by JNK II, but not p38 nor G-proteins. Conclusions/Significance: These findings suggest that HIV infection renders hepatocytes more susceptible to liver injury during disease states associated with enhanced TRAIL production such as HBV, HCV, or steatohepatitis.
AB - Background: HIV infected patients have an increased susceptibility to liver disease due to Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), alcoholic, and non-alcoholic steatohepatitis. Clinically, this results in limited options for antiretroviral therapy and accelerated rates of liver disease, causing liver disease to be the second leading cause of death for HIV infected patients. The mechanisms causing this propensity for liver dysfunction during HIV remains unknown. Methodology/Principal Findings: We demonstrate that HIV and/or the HIV glycoprotein gp120 ligation of CXCR4 on hepatocytes selectively up-regulates TRAIL R2 expression and confers an acquired sensitivity to TRAIL mediated apoptosis which is mediated by JNK II, but not p38 nor G-proteins. Conclusions/Significance: These findings suggest that HIV infection renders hepatocytes more susceptible to liver injury during disease states associated with enhanced TRAIL production such as HBV, HCV, or steatohepatitis.
UR - http://www.scopus.com/inward/record.url?scp=84864280100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864280100&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0004623
DO - 10.1371/journal.pone.0004623
M3 - Article
AN - SCOPUS:84864280100
SN - 1932-6203
VL - 4
JO - PLoS One
JF - PLoS One
IS - 2
M1 - e4623
ER -